Management of type 2 diabetes mellitus and cardiovascular risk -: Lessons from intervention trials

被引:34
|
作者
Yki-Järvinen, H [1 ]
机构
[1] Univ Helsinki, Dept Med, Helsinki 00029, Finland
关键词
D O I
10.2165/00003495-200060050-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although the diagnosis of type 2 (noninsulin-dependent) diabetes mellitus is made when blood glucose levels exceed values which increase the risk of microvascular complications, macrovascular disease is the major complication of type 2 diabetes mellitus. Both epidemiological and prospective data have demonstrated that treatment of hyperglycaemia is markedly effective in reducing the risk of microvascular disease but is less potent in reducing that of myocardial infarction, stroke and peripheral Vascular disease. Treatment of other cardiovascular risk factors, although by definition less prevalent than hyperglycaemia, appears to be more effective in preventing macrovascular disease than treatment of hyperglycaemia. In recent years, data from intervention trials have suggested that greater benefits with respect to the prevention of macrovascular disease can be achieved by effective treatment of hypertension and hypercholesterolaemia, and by the use of small doses of aspirin (acetylsalicylic acid) than by treating hyperglycaemia alone. On the other hand, the UK Prospective Diabetes Study (UKPDS), which examined the impact of intensive glucose and blood pressure (BP) control on micro- and macrovascular complications,is the only intervention trial to include only patients with type 2 diabetes mellitus. The UKPDS data, the epidemic increase in the number of patients with type 2 diabetes mellitus and their high cardiovascular risk have, however, initiated several new trials addressing, in particular, the possible benefits of treatment of the most common form of dyslipidaemia (high serum triglyceride and low high density lipoprotein cholesterol levels) in these patients. Type 2 diabetes mellitus is thus a disease associated with a high vascular risk, where the majority of patients need, and are likely to benefit from, pharmacological treatment of several cardiovascular risk factors provided treatment targets have not been achieved by life-style modification.
引用
收藏
页码:975 / 983
页数:9
相关论文
共 50 条
  • [1] Management of Type 2 Diabetes Mellitus and Cardiovascular RiskLessons from Intervention Trials
    Hannele Yki-Järvinen
    Drugs, 2000, 60 : 975 - 983
  • [2] Trials of cardiovascular risk factor management in type 2 diabetes
    Patel, Anushka
    Joshi, Rohina
    de Galan, Bastiaan
    CURRENT OPINION IN CARDIOLOGY, 2009, 24 (04) : 288 - 294
  • [3] Cardiovascular risk management in type 2 diabetes: From clinical trials to clinical practice
    Cusi, K
    ENDOCRINOLOGIST, 2001, 11 (06): : 474 - 490
  • [4] Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
    Kapoor, Karan
    George, Praveen
    Miller, Michael
    CARDIOLOGY, 2016, 135 (02) : 108 - 126
  • [5] Cardiovascular risk in type 2 diabetes mellitus
    Hohberg, C.
    Roth, W.
    Luebben, G.
    Forst, T.
    Gauert, S.
    Karagiannis, F.
    Reimer, T.
    Gottschall, V.
    Pfuetzner, A.
    DIABETES STOFFWECHSEL UND HERZ, 2007, 16 (03): : 173 - 177
  • [6] Pharmacological treatment of type 2 diabetes mellitus and cardiovascular risk: what is possible to understand from the trials?
    Consoli, Agostino
    Febo, Fabrizio
    GIORNALE ITALIANO DI CARDIOLOGIA, 2016, 17 (12) : 20S - 27S
  • [7] Electronic messaging intervention for management of cardiovascular risk factors in type 2 diabetes mellitus: A randomised controlled trial
    Fang, Ronghua
    Deng, Xuexue
    JOURNAL OF CLINICAL NURSING, 2018, 27 (3-4) : 612 - 620
  • [8] Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
    Lorber, Daniel
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 : 169 - 183
  • [9] Disease management strategies to optimize cardiovascular risk in type 2 diabetes mellitus
    O'Connor P.J.
    Sperl-Hillen J.M.
    Kottke T.E.
    Current Cardiovascular Risk Reports, 2009, 3 (1) : 71 - 77